Novo Nordisk invests in Eikonizo Therapeutics

Cambridge, USA-based Eikonizo Therapeutics today revealed it has secured an undisclosed equity investment from Novo Nordisk (NOV: N) through its Science2Medicine iNNvest initiative.

In addition to supporting the development of Eikonizo’s lead candidate, EKZ-102, a potential first-in-class, oral, CNS-penetrant, highly selective histone deacetylase 6 (HDAC6) inhibitor, the Novo Nordisk investment will also enable the advancement of novel Eikonizo HDAC6 inhibitors as potential disease-modifying therapeutics for cardiorenal disease.

Concurrent with its investment, Miriam Frieden, Novo Nordisk’s corporate vice president of early innovation, outreach and alliances, will join Eikonizo’s board of directors as a non-voting observer and Professor Bill Haynes, scientific corporate vice president, global drug Discovery, Novo Nordisk, will join Eikonizo’s scientific advisory board.